Perrigo joins Dexcel in filing for generic Prilosec

By Elaine Rigoli

Tampa, Fla., June 7 - The Perrigo Co. announced its association with Dexcel Pharma Technologies, Ltd.'s New Drug Application for a generic version of Prilosec OTC.

Under the agreement between the two companies, Perrigo will be the exclusive marketer and distributor of the Dexcel-developed and produced product for the store brand over-the-counter market in the United States and will share in the costs and potential benefits associated with the commercialization of this product.

Prilosec OTC (omeprazole delayed-release tablets 20 mg) acid reducer is indicated for the treatment of frequent heartburn and had annual sales of about $500 million through food, drug and mass merchandisers for the 12 months ended April 16, according to a news release.

Based in Or-Akiva, Israel, Dexcel is a specialty pharmaceutical company.

Perrigo is a health care supplier and manufacturer of over-the-counter pharmaceuticals and has headquarters in Allegan, Mich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.